Back

Impact of dapagliflozin on cardiac remodeling and sirtuin expression in rats with type 1 diabetes mellitus

29 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity and protection: from bench to bedside Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speakers

Photo
Associate Professor Marina Okoshi

Faculty of Medicine of Botucatu, UNESP, Botucatu (Brazil)

Photo
Miss Ana Marreiros

Botucatu (Brazil)

6 More presentations in this session

Presentation thumbnail
Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM
Professor A. Wang (Durham, US)
Abstract Slides Video
Presentation thumbnail
A UK multicentre experience of osimertinib related cardiovascular toxicity: real world patterns, risk stratification and surveillance
Doctor C. Simela (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Maternal fluconazole use during the third trimester and risk of QT prolongation in the offspring
Doctor G. Ninh (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Ranolazine ameliorates palmitic acid-induced insulin resistance in HL-1 cardiomyocytes by Ca2+/ CaMKII modulation: an in vitro investigation and population-based cohort study
Professor P. Liu (Tainan, TW)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of migalastat in Fabry's disease treatment with cardiac impact : a systematic review and meta-analysis
Mr L. Oldra (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity and protection: from bench to bedside

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of SGLT2 inhibitor dapagliflozin on myocardial protein profile in rats with long-standing Type 1 diabetes mellitus
thumbnail
Congress Presentation
Effect of SGLT2i on myocardial remodeling due to cardiorenal syndrome in rat model of heart failure
thumbnail
Congress Presentation
Empagliflozin improves metabolic profile and prevents myocardial and coronary dysfunction in diabetic rat hearts subjected to ischemia/reperfusion injury

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources